The PROTECT Trial for IgAN Patients
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
This study will be a randomized, active-control study that will help to determine if Sparsentan is effective at improving symptoms of IgAN.
Médico del ensayo/Coordinador del estudio
Marissa Baltazar
Correo electrónico Número de teléfono (720) 420-5691Nombre del sitio
Colorado Kidney Care
1601 East 19th Avenue, Suite 4300, Denver, Colorado 80218, United States
The PROTECT Trial for IgAN Patients
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
This study will be a randomized, active-control study that will help to determine if Sparsentan is effective at improving symptoms of IgAN.
Criterios de elegibilidad
Población de pacientes
IgA Nephropathy (IgAN)
Sobre el medicamento o la intervención
Qué implica para el paciente
Patients will take a daily dose of the study medication, and will be involved with the trial for about 2 years.
Nombre del patrocinador
Retrophin, Inc.
Matrícula estimada
280
Fecha estimada de finalización
April 2023
Sobre el estudio
Nombre del fármaco del estudio
Sparsentan
Objetivo del estudio
To evaluate the potential benefit of Sparsentan on kidney function by analyzing change in proteinuria (protein in urine) and estimated glomerular filtration rate (eGFR) as compared to current standard treatment.
Sobre el medicamento o la intervención
Sparsentan is a tablet taken orally.